Eli Lilly have at least one repurposed drug in Phase 3 trial to treat COVID : https://investor.lilly.com/news-releases/news-release-details/lilly-begins-phase-3-clinical-trial-baricitinib-hospitalized
Baricitinib is owned by Incyte, which popped about $4B USD in MC on the news its product was being trialled. I would expect a similar pop for PAA if MPL gets to Phase 3, say $6B AUD. So my rough calculation is PAA gets to $20 a share BEFORE MPLs effectiveness is proven (or not).
THEN, I’ll know the pressure the holders of 2 million shares are feeling this weekend.
Clinical Trials, page-301
-
- There are more pages in this discussion • 9 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
19.5¢ |
Change
-0.010(4.88%) |
Mkt cap ! $77.20M | |||
| Open | High | Low | Value | Volume |
| 19.5¢ | 19.5¢ | 18.8¢ | $342.8K | 1.779M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 52999 | 19.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 20.0¢ | 421000 | 3 |
View Market Depth
| Last trade - 16.10pm 27/06/2024 (20 minute delay) ? |
| PAA (ASX) Chart |